Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization

Ophthalmic Research

Volumn 40, Issue 1, 2007, Pages 19-25

  Yu, Wen Zhen ^a   Zou, He ^a   Li, Xiao Xin ^a   Yan, Zheng ^a   Dong, Jian Qiang ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Phosphatidylinositol 3 kinase; Retinal neovascularization; Vascular endothelial growth factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DIMETHYL SULFOXIDE; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; VASCULOTROPIN;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL MIGRATION; CELL NUCLEUS; CELL STIMULATION; CELL SURVIVAL; COLORIMETRY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; STAINING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANIMALS, NEWBORN; APYRASE; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CHROMONES; ENZYME INHIBITORS; ISCHEMIA; MACACA MULATTA; MICE; MICE, INBRED C57BL; MORPHOLINES; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37349039466     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111154     Document Type: Article

References (32)

1. Rarinaga M: Shedding light on blindness. Science 1995;267:452-453.
2. Williamson JR, Chang K, Frangos M: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-813.
3. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909.
4. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
5. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851-4856.
6. Bainbridge JW, Jia H, Bagherzadeh A, Selwood D, Ali RR, Zachary I: A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem Biophys Res Commun 2003;302:793-799.
7. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-216.
8. Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS: AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 2003;44:781-790.
9. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
10. Jiang BH, Zheng JZ, Aoki M, Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000;97:1749-1753.
11. Lal BK, Varma S, Pappas, PJ, Hobson RW, Duran WN: VEGF increases permeability of the endothelial cell monolayer by activation of PKB/Akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001;62:252-262.
12. Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockage of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-340.
13. Sausville EA, Elsayed Y, Monga M, Kim G: Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol 2003;43:199-231.
14. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-886.
15. Weylie B, Zhu J, Singh U, Ambrus S, Forough R: Phosphatidylinositide 3-kinase is important in late-stage fibroblast growth factor-1-mediated angiogenesis in vivo. J Vasc Res 2006;43:61-69.
16. Kwon YS, Hong HS, Kim JC, Sbin JS, Son Y: Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005;46:454-460.
17. Yu W-Z, Li X-X, She H-C, He P-Y, Dong J-Q, Rui M, Ma D-L: Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. Ophthalmic Res 2003;35:239-246.
18. Kwon YS, Kim JC: Inhibition of corneal neovascularization by rapamycin. Exp Mol Med 2006;38:173-179.
19. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H: Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 1999;40:1624-1629.
20. Hu L, Hofmann J, Jaffe RB: Phosphatidylinositol 3-kinase mediates angiogenesis and vascularization permeability associated with ovarian carcinoma. Clin Cancer Res 2005;11:8208-8212.
21. Penn JS, Tolman BL, Lowery LA: Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993;34:576-585.
22. Dejneka NS, Kuroki AM, Fosnot J, Tang WX, Tolentino MJ, Bennett J: System rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-972.
23. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-886.
24. Weylie B, Zhu J, Singh U, Ambrus S, Forough R: Phosphatidylinositol 3-kinase is important in late-stage fibroblast growth factor-1-mediated angiogenesis in vivo. J Vasc Res 2006;43:61-69.
25. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, Miyazaki J, Suda T, Itoh H, Nakao K, Mak TW, Nakano T, Suzuki A: The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005;19:2054-2065.
26. Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, Coukos G: The oncogene phosphatidylinositol 3-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003;63:4225-4231.
27. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851-4856.
28. Friedlander M, Theesfeld C, Sugita M: Involvement of integrins αv/β3 and αv/β5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996;93:9764-9769.
29. Penn JS, Rajaratnam VS, Collier RC, Clarke AF: The effects of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283-290.
30. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-S67.
31. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB: Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004;64:2552-2560.
32. Datta SR, BrunetA, Greenberg ME: Cellular survival:a play in three Akts. Genes Dev 1999;13:2905-2927.